5/3
09:44 am
tgtx
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/3
06:01 am
tgtx
Why TG Therapeutics Stock Was Rocketing Higher This Week [Yahoo! Finance]
Low
Report
Why TG Therapeutics Stock Was Rocketing Higher This Week [Yahoo! Finance]
5/2
02:07 pm
tgtx
TG Therapeutics, Inc. (NASDAQ: TGTX) had its price target raised by analysts at HC Wainwright from $45.00 to $49.00. They now have a "buy" rating on the stock.
Low
Report
TG Therapeutics, Inc. (NASDAQ: TGTX) had its price target raised by analysts at HC Wainwright from $45.00 to $49.00. They now have a "buy" rating on the stock.
5/2
09:06 am
tgtx
TG Therapeutics, Inc. (NASDAQ: TGTX) had its price target raised by analysts at LADENBURG THALM/SH SH from $39.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
TG Therapeutics, Inc. (NASDAQ: TGTX) had its price target raised by analysts at LADENBURG THALM/SH SH from $39.00 to $40.00. They now have a "buy" rating on the stock.
5/1
07:12 am
tgtx
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/1
07:00 am
tgtx
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Medium
Report
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
4/30
04:55 pm
tgtx
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
High
Report
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
4/18
02:12 pm
tgtx
TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $39.00 price target on the stock.
Low
Report
TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $39.00 price target on the stock.
4/18
02:12 pm
tgtx
TG Therapeutics, Inc. (NASDAQ: TGTX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $25.00 price target on the stock.
Low
Report
TG Therapeutics, Inc. (NASDAQ: TGTX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $25.00 price target on the stock.
4/18
02:12 pm
tgtx
TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
Low
Report
TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
4/18
07:30 am
tgtx
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Low
Report
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
4/18
07:23 am
tgtx
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis [Yahoo! Finance]
Low
Report
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis [Yahoo! Finance]
4/18
07:00 am
tgtx
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Low
Report
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
4/17
10:51 am
tgtx
TG Therapeutics: The Cloud Over Briumvi [Seeking Alpha]
Low
Report
TG Therapeutics: The Cloud Over Briumvi [Seeking Alpha]
4/15
07:30 am
tgtx
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Low
Report
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
4/12
07:07 pm
tgtx
TG Therapeutics: BRIUMVI Development Could Lead To Great Results [Seeking Alpha]
Low
Report
TG Therapeutics: BRIUMVI Development Could Lead To Great Results [Seeking Alpha]
3/22
03:30 am
tgtx
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Low
Report
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
3/21
01:18 pm
tgtx
PI3K Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the Domain [Yahoo! Finance]
Neutral
Report
PI3K Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the Domain [Yahoo! Finance]
3/19
07:28 am
tgtx
Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals? [Yahoo! Finance]
Low
Report
Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals? [Yahoo! Finance]
3/8
07:30 am
tgtx
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Medium
Report
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
3/1
09:00 am
tgtx
TG Therapeutics: Briumvi Growth Story Appears Intact [Seeking Alpha]
Low
Report
TG Therapeutics: Briumvi Growth Story Appears Intact [Seeking Alpha]
3/1
07:46 am
tgtx
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum [Yahoo! Finance]
Medium
Report
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum [Yahoo! Finance]
3/1
07:30 am
tgtx
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Medium
Report
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2/29
09:33 am
tgtx
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
08:17 am
tgtx
TG Therapeutics, Inc. (NASDAQ: TGTX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $12.00 to $13.00. They now have a "neutral" rating on the stock.
Low
Report
TG Therapeutics, Inc. (NASDAQ: TGTX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $12.00 to $13.00. They now have a "neutral" rating on the stock.